Medicom International Conference Series in Dermatology 28th EADV Congress European Academy of Dermatology and Venereology 9-13 october 2019 • Madrid • Spain EVIEWED R PEER- CONFERENCE CONFERENCE REPORT Late-Breaking News Emerging Therapies Spotlight on Psoriasis JAK inhibitors are a fascinating The IL-4/IL-13 blocker dupilumab Ten-year data from the ESPRIT novel drug class entering the der- leads to rapid itch reduction in registry shows the importance of matologic arena. The JAK1 and adolescents. The safety profile is achieving good control of moderate- JAK2 inhibitor baricitinib showed similar to that in adults. to-severe psoriasis. to be effective in patients with moderate-to-severe atopic derma- titis in a phase 3 trial. read more on PAGE 5 read more on PAGE 10 read more on PAGE 13 Editor Peter van de Kerkhof, Radboud University Medical Center, the Netherlands MEDIC AL PUBLISHERS Contents Letter from the Editor 3 Late-Breaking News 3 IL-17A blocker effective in paediatric psoriasis patients 3 Rituximab beats mycophenolate mofetil in pemphigus vulgaris COLOPHON 4 Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata Editor Prof. Peter van de Kerkhof Radboud University Medical Center, 5 Acne highly influenced by climate, pollutants, and unhealthy diet the Netherlands 5 JAK inhibition plus TCS lead to high clearance rates in AD Advisory Board Prof. Margarida Gonçalo 6 No cancer risk with long-term use of calcineurin inhibitor in Coimbra University Hospital, Portugal children with AD Dr Tom Hillary UZ Leuven, Belgium 7 Green light for a second JAK inhibitor in AD 7 Topical ruxolitinib effective in vitiligo Publishing Director Paul Willers Editorial Manager Lisa Colson 8 Emerging Therapies Editorial Coordinators Sanne Lauriks 8 Small molecules: interesting novel treatment options in AD Dr Joery Goossens 9 IL-1α blockade: a new treatment option in AD Medical Writer Dr Susanne Kammerer 10 IL-4/IL-13 blockade leads to rapid itch reduction in adolescents Dr Karin Drooff 10 How to manage conjunctivitis in AD patients treated with a biologic Production Manager Desiree Heijl 11 Biologics: increasingly used in paediatric dermatology Graphic Design MOOZ grafisch ontwerp ISSN 2468-8762 19:21 12 Spotlight on Psoriasis 12 IL-17 blocker: effective and safe in patients with comorbidities 13 ESPRIT registry: sharp decline in mortality in patients treated All rights reserved. No part of this publication may be reproduced, distributed, or transmitted with a TNF blocker in any form or by any means, including photocopying, recording, or other 13 Psoriasis and NAFLD: new data on the hepato-dermal axis electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical 13 Novel selective IL-23 blocker equally effective in patients with reviews and certain other noncommercial uses permitted by copyright law. metabolic syndrome Copyright ©2019 Medicom Medische Uitgeverij BV 14 Selective IL-23 blocker crushes fumaric acids in all assessed Disclaimer: efficacy endpoints Our independent peer-reviewed Medicom Conference Reports are made 15 No hint of teratogenicity through ixekizumab possible by sponsoring. The ideas and opinions expressed in this journal or other associated publications do not necessarily reflect those of Medicom Medical Publishers. Although great care has been taken in compiling 15 New Insights in Photoprotection the content of this publication, Medicom is not responsible or liable in 15 Systemic photoprotection: a valuable addition to topical sun any way for the currency of the information, for any errors, omissions or inaccuracies in the original articles, or for any consequences arising from protection the content. Products mentioned in this report may not be covered by marketing authorisation in some countries. Product information, applicable 16 The underestimated effect of visible light in your country, should be reviewed before prescribing. The mention of any product, service, or therapy in this publication should not be construed as 17 Urticaria an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent 17 Comorbidities more common in chronic urticaria, psoriasis, and AD experience and knowledge of the patient, to determine drug dosages 17 D-Dimer as future biomarker in CSU management? and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently 18 Ligelizumab for CSU: symptom control and high response rates provided by the manufacturer of each drug to be administered to verify in re-treatment the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. Medicom assumes no 19 Rosacea – From New Spectrum to New Therapy responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any 19 The Rosacea Tracker may aid clinical decision-making errors or omissions. 19 New guidance on rosacea therapy according to phenotype 20 Best of the Posters 20 Above-the-neck melanoma more prone to metastases 21 Reduced sleep quality in dermatoses influenced by itch and pain MEDIC AL PUBLISHERS 21 Anxiety and depression are common in families of AD infants 22 Certolizumab efficacious for head and neck psoriasis Head Office Postal address Medicom Medical Publishers Medicom Medical Publishers Faas Eliaslaan 5 PO Box 90 3742 AR Baarn 3740 AB Baarn The Netherlands The Netherlands Join us on LinkedIn Telephone +31 85 4012 560 MEDIC AL PUBLISHERS E-mail [email protected] Letter from the Editor Prof. Peter C.M. van de Kerkhof Dear Reader, Biography Peter C.M. van de Kerkhof is The 28th EADV Congress brought innovations to derma- emeritus Professor of Dermatology and immediate past chairman of tologists in many respects. In this overview, we have the Department of Dermatology attempted to be balanced and to focus on the presenta- of Radboud University Nijmegen. tions which are practically relevant. The new insights He is currently the coordinating into the pathogenesis of inflammatory skin diseases Medical Officer of the International have provided biomarkers that are becoming significant Psoriasis Council and chair of the to dermatology. Introduction of new treatments in in- scientific advisory board of the Dutch burn association. He has flammatory dermatoses requires a critical and adequate been working for many years on positioning of new treatments in daily practice. the pathogenesis and treatment of psoriasis. He has published In particular in psoriasis, the innovations found their way more than 700 publications in to real clinical practice: In children with psoriasis anti-IL-17 peer-reviewed journals and has are currently explored. On ixekizumab, 78% of children given many presentations on invitation at international with psoriasis reached a PASI 90 response. Comorbidities conferences. He has served as are also relevant to psoriasis. Studies on the efficacy of president of the ESDR, EDF, and treatments in comorbid patients was similar to the efficacy the International Psoriasis Council, in patients without comorbidities. A remarkable study was and was board member of presented, showing that patients with moderate-to-severe various international societies. psoriasis treated with adalimumab had a 58% lower stan- Current interests are: pathogenesis and development of biomarkers dardised mortality rate compared with the general popula- for psoriasis; real clinical practise tion. Comorbidities matter and evidence is accumulating research; and personalised that adequate treatment of psoriasis may prevent their de- medicine. velopment. In atopic dermatitis, treatment innovation is a revolution: various JAK inhibitors, anti-IL-4/IL-13, PDE4 in- Conflict of Interest Statement: Consultancy services for: Celgene, hibitors, and IL-1 alpha blockade. Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma, Furthermore, this overview provides information on: Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant. photo-protection by systemic treatment, comorbidities in Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO urticaria, and a “tracker” to classify rosacea by phenotype, Pharma, Sandoz, Bristol Meyer Squibb. which makes sense as a subdivision in light of treatment selection. The future for inflammatory dermatoses of the skin is bright. Best regards, Prof. Peter C.M. van de Kerkhof CONFERENCE REport - Eadv 2019 Late-Breaking News IL-17A blocker effective in paediatric psoriasis Therapy with the IL-17 inhibitor also led to a reduction in itch: patients 71% of patients treated with ixekizumab compared to 20% of In a phase 3 study, the interleukin (IL)-17 blocker ixeki- placebo patients achieved an improvement in itch of ≥ 4 NRS zumab showed a similar efficacy in paediatric patients score. As well as a clinically relevant gain in quality of life, with moderate-to-severe psoriasis as previously demon- assessed in the Children´s Dermatology Life Quality Index: strated in adult patients [1]. 65% of patients in the ixekizumab group and 23% of placebo patients gained a Children´s Dermatology Life Quality Index Although the first symptoms of psoriasis symptoms